Fusion Antibodies's EBIT per Share for the
six
months ended in Sep. 2025 was £-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was £-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 28.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 11.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Fusion Antibodies's EBIT per Share or its related term are showing as below:
LSE:FAB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -122.4 Med: 1.05 Max: 28
Current: 28
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Fusion Antibodies was 28.00% per year. The lowest was -122.40% per year. And the median was 1.05% per year.
LSE:FAB's 3-Year EBIT Growth Rate is ranked better than 65.44% of 1172
companies
in the Biotechnology industry
Industry Median: 15.4
vs LSE:FAB: 28.00
Fusion Antibodies (LSE:FAB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Fusion Antibodies EBIT per Share Related Terms
Fusion Antibodies EBIT per Share Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a EBIT per Share of £-0.01 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Fusion Antibodies and its competitors. According to the industry distribution chart, Fusion Antibodies ranks #405 out of 1172 companies in the Biotechnology industry, placing it in the top 34.6%.
Is Fusion Antibodies' EBIT per Share too high?
Fusion Antibodies' current EBIT per Share is £-0.01. Based on the distribution chart, Fusion Antibodies ranks #405 out of 1172 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fusion Antibodies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #405 out of 1172 companies for EBIT per Share. This puts Fusion Antibodies in the upper half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Fusion Antibodies and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current EBIT per Share is £-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.11 — trading 175% above its estimated fair value. The current EBIT per Share is £-0.01. Fusion Antibodies' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current EBIT per Share is £-0.01 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.11 is trading 175% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
EBIT per Share: £-0.01
GF Value™: £0.04 vs. price of £0.11 (175% above fair value)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
33GF Score
Get the complete analysis for LSE:FAB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
